Grants and Contributions:

Back to search

Title:

Precision Drug Delivery via Laser-Activated Microfluidic Fibers

Agreement Number:

1034613

Agreement Value:

$242,500.00

Agreement Date:

Sep 1, 2025 - Aug 31, 2026

Description:

This project aims to develop and validate a novel platform for laser-assisted targeted drug delivery using LMI's proprietary picosecond mid-infrared laser technology. This technology enables precise ablation of tissues and when coupled to a microfluidic drug channel, the optic probe can deliver localized therapeutics with high resolution and minimal invasiveness. LMI holds foundational IP specific to this application covering fiberoptic laser-drug delivery systems in addition to the original core IP portfolio covering the unique laser tissue interaction. The platform will be validated in, phantom tissue, ex vivo and animal models, focusing on applications in high-value organ systems: prostate, brain, lung, and pancreas.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Toronto, Ontario, CA M8Z 2T7

Reference Number:

172-2025-2026-Q2-1034613

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

808272470

Recipient Type:

For-profit organization

Recipient's Legal Name:

Light Matter Interaction Inc.

Federal Riding Name:

Etobicoke--Lakeshore

Federal Riding Number:

35028

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

339990